[Federal Register Volume 60, Number 229 (Wednesday, November 29, 1995)]
[Notices]
[Pages 61265-61267]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-29092]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Health and Human Services 
Department.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected 

[[Page 61266]]
inventions to extend market coverage for U.S. companies and may also be 
available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications and issued patents listed below may be obtained by writing 
to John Fahner-Vihtelic, Technology Licensing Specialist, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Box 13, Rockville, Maryland 20852-3804 (telephone 301/496-
7735 ext 285; fax 301/402-0220). A signed Confidential Disclosure 
Agreement (CDA) will be required to receive copies of the patent 
applications. Requests for copies of issued patents do not require the 
execution of a CDA.

Methods For Determining The Presence Of Functional p53 In Mammalian 
Cells

Fornace, A.J., Kastan, M.B. (NCI)
Filed 10 Aug 94
Serial No. 08/288,872 (CON of 07/974,960)

    The protein p53 is involved in tumorigenesis. Recent observations 
have indicated that the gene encoding p53 is a tumor suppressor gene; 
however, mutation or deletion of this gene results in loss of this 
suppressor function. Mutations of the p53 gene have been demonstrated 
in tumors of the colon, breast, lung, ovary, bladder, and other organs, 
making the p53 gene the most commonly mutated gene yet identified in 
human cancers. While currently used assays can detect the presence of 
wild-type or mutant p53 protein in mammalian cells, they cannot 
accurately determine the presence of functional p53 protein in these 
cells, which is necessary to determine the biological function of 
functional p53 and to develop subsequent diagnostic modalities using 
functional p53. This invention describes a specific gene whose 
expression is dependent on the presence of functional p53 in cells and 
tumors, as well as methods by which the presence of this gene may be 
detected. It also describes a diagnostic kit utilizing a nucleic acid 
sequence capable of binding functional p53, which is then measured to 
detect p53 presence. Issuance of a patent on this invention is 
currently pending. [portfolio: Cancer--Diagnostics]

Novel B-Lymphoma Cell Line And Antigen

Bock, G.H., Nelson, D.L., Kurman, C.C., Fleisher, T.A. (NCI)
Filed 9 Aug 94
Serial No. 08/287,718 (FWC of 07/934,106)

    Various cell lines of B-cell lineage have been produced, but none 
have been of tumor cell origin. This case provides an IL-6 dependent B-
cell lymphoma cell line, designated DS-l. The invention further 
provides a monoclonal antibody which reacts with the cell line and a 
method for detecting the presence of neoplastic cells by detecting the 
presence of an antigen on a cell which is not normal for that cell 
type. [portfolio: Cancer--Diagnostics; Cancer--Research Reagents]

Novel Human ras-Related Oncogenes Unmasked By Expression cDNA Cloning

Aaronson, S., Chan, A., Miki, T. (NCI)
Filed 24 May 94
Serial No. 08/247,946

    A family of small G-proteins encoded by H-, K-, and N-ras is 
frequently activated as oncogenes in a wide variety of human tumors. 
Activation is usually due to a point mutation within the coding 
sequence which results in the molecule to be constitutively in the GTP 
bound (active) state. In normal cells, these proteins are coupled to 
growth factor signaling pathways and appear to cause proliferation or 
differentiation. Over the past several years, cloning efforts by many 
laboratories have greatly expanded the number of ras-related proteins, 
to include R-ras, K-rev-l/rap and TC21. The present invention relates 
to a mutant TC21 protein that was cloned from an expression cDNA from a 
ovarian carcinoma cell line. Based upon the finding that an oncogenic 
form of TC21 exists, the present invention also relates to the 
generation of point mutations in R-ras for expression study. The 
present invention also relates to methods of diagnosing cancers or 
monitoring disease progression by detecting mutant forms of R-ras or 
TC21 at the protein or gene level. [portfolio: Cancer--Diagnostics; 
Cancer--Research Reagents]

Immortalized Adult Human Prostate Epithelial Cell Lines

Rhim, J.S., Webber, M.M. (NCI)
Filed 28 Apr 94
Serial No. 08/234,843

    This invention relates to cell lines which are useful in testing 
compounds for anti-carcinogenic, anti-neoplastic, anti-invasive, or 
anti-metastatic activity by growing the cell line in the presence of 
the subject compounds. The cell lines contain DNA of a human Papilloma 
virus (HPV), either alone or with an activated viral ras oncogene, 
e.g., v-Ki-ras. The HPV immortalized line is not tumorigenic; however, 
the V-Ki-ras transformed HPV cell line is tumorigenic. They are useful 
for determining causes, treatment, and prevention of prostate cancer, 
benign prostate hyperplasic, male infertility, birth defects, aging, 
and assessment of environmental toxic agents. [portfolio: Cancer--
Research Reagents]

Pulsed Low Frequency EPR Spectrometer And Imager

Bourg, J., Cherukuri, M., Mitchell, J., Mirotznik, M., Roth, B., 
Subramanian, S. (NCI)
Serial No. 08/097,811
Patent Issued 7 Feb 95
U.S. Patent No. 5,387,867

    This application describes an Electron Paramagnetic Resonance (EPR) 
spectroscopy imaging system. This system generates broadband pulses 
having a RF carrier frequency that is not highly absorbed by biological 
materials. The pulse generating system includes up and down chirp 
converters for frequency modulating of a carrier frequency and 
compression of the frequency modulated pulse to form a broadband 
excitation pulse of high energy. This technology's function has been 
proven and could form the basis of a clinical imaging device capable of 
high sensitivity to free radical species in human patients. [portfolio: 
Devices/Instrumentation--Diagnostics, electron paramagnetic resonance]

Phosphonoalkyl Phenylalanine Compounds Suitably Protected For Use In 
Peptide Synthesis

Burke, T.R, Smyth, M.S., Lim, B.B. (NCI)
Filed 8 Jun 93
Serial No. 08/073,088

    A novel class of phosphononodifluoromethyl phenylalanine 
(``F2Pmp'') derivatives have been developed which are suitable for 
the synthesis of peptides containing the phosphotyrosyl (pTyr) mimetic, 
F2Pmp. These analogues bear Boc or Fmoc protection at the 
N-position for either solution or solid-phase peptide 
synthesis using standard techniques. A number of studies have shown 
that peptides containing the F2Pmp residue show utility as 
inhibitors of src homology 2 (SH2) domain binding interactions and of 
phosphotyrosyl phosphatases. Unlike pTyr residues, the F2Pmp 
moiety is stable to both chemical and phosphatase-mediated hydrolysis, 
making it an attractive replacement for pTyr in signal transduction 
peptides. [portfolio: Cancer--Research Reagents]

Monoclonal Antibodies To Prostate Cells

Pastan, I. (NCI)
Filed 8 Oct 92
Serial No. 07/958,140

    Monoclonal antibodies which bind to an antigen associated with 
prostate cells, including prostate cancer, can be 

[[Page 61267]]
used either individually or conjugated to drugs, labels, radioisotopes, 
or cytotoxins to target delivery of the conjugated to prostate cells. 
The antibodies are thus useful in a variety of diagnostic and 
therapeutic applications involving prostate cancer. A hybridoma cell 
line secreting monoclonal antibody PR1 is also provided, as well as 
methods for screening for the presence of metastatic prostate cancer. 
[portfolio: Cancer--Therapeutics]

Antibodies To Human LINE-1 p40 Protein

Fanning, T.G. (NCI)
Serial No. 07/750,044
Patent Issued 18 Jan 94
U.S. Patent No. 5,280,108

    Antibodies to the human LINE-1 retrotransposon offer a powerful new 
tool for studying tumors. In most cell lines and tissues, human LINE-1 
sequences (LIHs) are not expressed; however, LIH-specific RNA and 
proteins have been detected in cell lines and tissues derived from 
human germ cell tumors (teratocarcinomas) and breast tumors. These LIH 
antibodies, which are specific for the p40 protein portion of the 
retrotransposon, can be used for determining LIH expression in tumor 
cells and determining the role this retrotransposon plays in these 
cells. [portfolio: Cancer--Research Reagents]

Cartilage-Derived Morphogenetic Proteins

Luyten, F.P., Moos, M., Chang, S. (NIDR)
PCT Application PCT/US94/12814 filed 7 Nov 94
DHHS Reference No.: E-138-94/0

    The present invention provides a cartilage-derived extract which 
initiates and promotes ectopic cartilage and bone development in vivo 
and recombinant cartilage-derived morphogenetic proteins which promote 
development of musculoskeletal tissues in vivo. These products will be 
useful in the therapeutic induction, repair, and maintenance of 
skeletal tissues. These compounds show promise for the healing of joint 
surface lesions and repair or reconstruction of cartilaginous tissues. 
They are also useful as growth factors for cells of the chondrocyte 
lineage which, expanded ex vivo, can be implanted into an individual 
where cartilage growth is desired. In addition, cloned polynucleotides 
encoding these proteins will be effective diagnostic reagents for 
detecting genetic abnormalities associated with poor skeletal 
development. [portfolio: Cancer--Therapeutics, biological response 
modifiers, growth factors]

    Dated: November 20, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-29092 Filed 11-28-95; 8:45 am]
BILLING CODE 4140-01-P